THE hemolytic anemia associated with erythrocyte pyruvate kinase deficiency is of variable severity 1–17 and probably of variable cause. In some cases severe aberrations of erythrocyte shape ...
ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –– ...
USA-based Agios Pharmaceuticals has announced that the ACTIVATE-Kids Phase III study of mitapivat in children aged 1 to <18 ...
Hosted on MSN2mon
Here's Why Agios Stock Plummeted More Than 20% on MondayPyrukynd is currently approved by the FDA to treat adults with pyruvate kinase deficiency, a rare and debilitating blood disorder. The drug is currently the sole marketed product in the company ...
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that the ACTIVATE-Kids Phase 3 study of mitapivat in children aged 1 to <18 years with PK deficiency who are not regularly transfused achieved its ...
AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.
Research and Development (R&D) Expenses: R&D expenses were $82.8 million for the fourth quarter of 2024, compared to $77.5 million for the fourth quarter of 2023, and $301.3 million for the full year ...
Feb. 13, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK ... 1 to <18 years with PK deficiency who are not regularly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback